Smarter hospitals start here

We are building the foundation for clinical evidence — transforming unstructured hospital data into a standardised, queryable format, and the superintelligence reasoning layer on top of it.

Read the whitepaperLearn more →
Problem

Hospitals generate vast amounts of data — but can't use it for decision-making.

Simple tasks — like answering which departments have the highest rate of preventable complications — take weeks to resolve manually.

Pipeline

Unstructured notes to queryable data.

The Data Engine transforms hospital data — in any language — into structured format with standardised medical codes that your teams can query, audit, and bill against.

Amorphous is ISO 27001, ISO 27017, and ISO 42001 compliant, and our technologies are certified as an Artificial Intelligence Management System.

Latency
~2 m
Entity Recall
97.8%
Ontologies
SNOMED · ATC · LOINC · ICD-10 · RxNorm
Audit Artifacts
SQL, Python Code, Visualisations
01Input
Discharge Note
Patient denies chest pain.
Hx HTN, DM2 — on metformin 500mg BID.
Troponin 0.8 ng/mL, elevated.
02Structure
Data Engine
HypertensionSNOMED CT 38341003
Type 2 diabetes mellitusICD-10 E11
Metformin 500mgRxNorm 6809
Troponin (elevated)LOINC 6598-7
03Reason
Striata
Q: Compare HbA1c trajectory — insulin vs oral antihyperglycemics.
↳PlanningCohort Definition
↳Data QuerySQL Code
↳AnalysisWelch's t-test
↳VisualisationBar Chart
↳ReportMethodology & Findings
04Output
Auditable Report
Δ HbA1c · 12 months
Insulin
−0.84%
n = 218
Oral
−0.18%
n = 194
Δ = 0.66 ppp = 0.005
Striata

Operational, financial, and clinical insights — in minutes.

Striata answers the questions your analysts would need weeks for. Our tools automate manual and repetitive tasks, to reduce cost and increase revenue.

Striata
QuestionsProcess Document
EN
N
‹Post-MI medication adherence
ChatSuccess
Myocardial infarctionSNOMED CTI21 · Acute myocardial infarctionICD-10Atorvastatin oral productRXNORMShow all 38 codes
⌕
Dataset Query
▦
Visualization
◱
Report
Post-MI Medication Adherence
Report ready — see findings panel.
Show Suggestions
⌘  Ask a follow-up…
↑
Findings
Create ReportExplore Data
Post-MI Medication Adherence
Summary
Of 2,847 post-MI patients, 62% remained on secondary-prevention therapy at 12 months. Therapy lapsed most in the 65–79 age group (48% adherence vs. 71% for under-65).
Figure 1
Secondary-prevention adherence at 12 months
80%
60%
40%
20%
0%
71%
<65
48%
65–79
41%
80+
Age group
<65
65–79
80+
Sample Questions

What COOs, finance teams, and clinical leads ask.

Swipe for more
Chief Operating Officer asks Striata:
"What are the primary bottlenecks in the acute myeloid leukemia pathway that push length-of-stay above the national average?"
Lab Notes
Making sense of unstructured data in hospitals

Read the whitepaper.

How the Data Engine structures clinical records, the architecture behind Striata, and the benchmarks that drive development.

Backing

$2.2M pre-seed, backed by operators.

Led by Specialist VC and Calm/Storm, with backing from PurposeTech, Z Fellows, BADideas.fund, Outlast Fund and Plug and Play, alongside leading US and EU angels.

Investors

Specialist VCCalm/StormPurposeTechZ FellowsBADideas.fundOutlast FundPlug and Play
Contact

Deploy Striata now.Let's talk.

For partnerships

hello@amorphous.health
Get in touch